Skip to content

医疗人员

通过觅瑞MiRXES开创性miRNA分析工作,我们发现了新的miRNA生物学和生物标志物,开发了革命性的miRNA应用,利用它们诊断疾病和解决实际问题。觅瑞的生物技术研发进展正在帮助企业、医院、临床医生、研究人员、医疗科技公司和患者实现个性化健康管理和精准医疗。

筛无忧之胃癌早筛

胃癌筛查变得简单

MiRXES is a world leader in applying microRNA detection technologies to discover novel microRNA biomarkers, and to develop clinical assays and other practical applications.

In 2012, the MiRXES R&D team kickstarted a collaboration with the Singapore Gastric Cancer Consortium, led by Prof. Yeoh Khay Guan and Prof. Jimmy So. MiRXES developed a microRNA-based assay for early detection of gastric cancer. Working with clinicians and researchers from the National University Hospital of Singapore (NUH), Tan Tock Seng Hospital (TTSH), A*STAR’s Diagnostics Development Hub (DxD Hub), and the Bioprocessing Technology Institute, the team developed GASTROClear, which went on to receive regulatory approval in Singapore in 2019. GASTROClear is the world’s first microRNA-based blood test for early detection of gastric cancer that is approved for commercial use.

GASTROClear’s performance has been validated in a prospective clinical study across more than 5,000 subjects in Singapore. The test is manufactured in Singapore by MiRXES, and was approved by the Health Sciences Authority (HSA) of Singapore in May 2019. Doctors and clinics in Singapore can order the test through Tan Tock Seng Hospital’s Molecular Diagnostic Laboratory (MDL) or through our appointed distributor Innovative Diagnostics Pte Ltd.

播放视频

可在新加坡提供检测服务

全球首个

用于早期胃癌检测的miRNA血液试剂产品

检测早期胃癌

(0-2期)高精准度

经新加坡

健康科学管理局(HSA)批准获得医疗三类证(class c);获得CE标志;产品根据 ISO13485标准 制造。

可在新加坡提供检测服务

乳腺癌早筛产品

于2020年发布

肺癌早筛产品

于2020年发布